What are the risks of using lenvatinib with other chemotherapy drugs?

Lenvatinib (Lenvatinib) is a multi-target tyrosine kinase inhibitor (TKI) that mainly targets VEGFR1-3, FGFR1-4, PDGFRα, RET and KIT, are widely used in treatment Malignant tumors such as hepatocellular carcinoma (HCC), differentiated thyroid cancer (DTC) and renal cell carcinoma (RCC). In clinical practice, lenvatinib is often used in combination with other chemotherapy drugs to improve efficacy. However, due to the mechanism of action of lenvatinib and its unique adverse effect profile, combination chemotherapy may pose a series of potential risks that require close attention and management.

1. Aggravate vascular-related adverse reactions (hypertension, bleeding, thrombosis)

Lenvatinib Inhibiting theVEGFR pathway will damage vascular endothelial function, leading to hypertension, increased risk of bleeding, and thrombosis. These risks may be further exacerbated if used in combination with certain chemotherapy drugs that increase the risk of blood clots or bleeding (eg, bevacizumab, cisplatin, pemetrexed).

High blood pressure:

Lenvatinib The incidence of induced hypertension can be as high as40%-70%, especially when used in combination with chemotherapy.

Some chemotherapy drugs (such as cisplatin) may also cause renal toxicity and hypertension, increasing cardiovascular burden.

Management measures: Patients taking combined treatment regimens should regularly monitor their blood pressure and, if necessary, use antihypertensive drugs (such asACEI, ARB or calcium channel blockers) for control.

Increased risk of bleeding:

VEGFRInhibition can cause fragile capillaries, which may cause nosebleeds, gastrointestinal bleeding or severe cerebral hemorrhage when combined with chemotherapy.

Management measures: Avoid excessive use with anticoagulants (such as warfarin, heparin) and closely monitor platelet levels and bleeding symptoms.

Thromboembolic risk:

Lenvatinib may cause venous thromboembolism (VTE) and arterial thrombotic events (ATE), and chemotherapy (such as cisplatin) may also increase the risk of thrombosis.

Management measures: For high-risk patients (such as those with a history of cardiovascular disease), use with caution and consider prophylactic anticoagulation.

2. Aggravate liver and kidney toxicity

Lenvatinib is mainly metabolized by the liver. Some chemotherapy drugs (such as cisplatin, pemetrexed, and doxorubicin) can also cause toxicity to the liver and kidneys. Combined use may result in hepatic impairment or acute kidney injury (AKI).

Hepatotoxicity:

VEGFRInhibition may affect liver blood flow, causing elevated liver enzymes, cholestatic liver damage, and even liver failure.

Chemotherapy drugs (such as doxorubicin) may also cause abnormal liver function.

Management measures: Regular monitoring of AST, ALT, and bilirubin. For patients with abnormal liver function, dose reduction or medication suspension may be considered.

Nephrotoxicity:

Lenvatinib may affect the glomerular filtration rate through VEGFR inhibition, leading to proteinuria and decreased renal function.

Many chemotherapy drugs (such as cisplatin) themselves are nephrotoxic and their combined use may aggravate kidney damage.

Management measures: It is recommended Monitor creatinine and urine protein levels, and maintain adequate hydration to reduce renal damage.

3. Increase gastrointestinal adverse reactions (nausea, diarrhea, decreased appetite)

Both lenvatinib and chemotherapy may cause Gastrointestinal side effects, such as nausea, vomiting, diarrhea, and loss of appetite. Combined use may aggravate these adverse reactions and affect the patient's nutritional status.

Nausea and vomiting:

Lenvatinib Used alone may cause nausea and loss of appetite. Some chemotherapy drugs (such as cisplatin and pemetrexed) are also highly emetogenic drugs.

Management measures: Vomiting can be controlled with 5-HT3 receptor antagonists (such as ondansetron) or NK1 receptor antagonists (such as aprepitant).

Diarrhea:

Lenvatinib may affect the intestinal mucosa and cause diarrhea. Certain chemotherapy drugs (such as irinotecan) may also induce severe diarrhea .

Management measures: You can use montmorillonite powder and loperamide to control diarrhea and maintain water and electrolyte balance.

4. Increased risk of fatigue and bone marrow suppression

Lenvatinib may cause asthenia, fatigue and thyroid dysfunction, while some chemotherapy drugs (such as taxanes and platinums) can also cause asthenia, anemia and bone marrow suppression. When used together, these symptoms may be aggravated.

Myelosuppression (leukocyte, thrombocytopenia):

Chemotherapy can directly suppress bone marrow, and lenvatinib may affectVEGFR related bone marrow microenvironment and aggravate cytopenias.

Management measures: Monitor blood routine and use G-CSF (granulocyte colony-stimulating factor) or adjust the dose if necessary.

Thyroid dysfunction:

Lenvatinib may cause low thyroid function (hypothyroidism), which may worsen fatigue symptoms.

Management measures: It is recommended to regularly detect TSH, T3, T4 levels, and supplement thyroid hormone if necessary.

Summary and management suggestions

The combined use of lenvatinib and chemotherapy can enhance the anti-tumor effect, but it also brings risks such as vascular events (hypertension, thrombosis, bleeding), liver and kidney toxicity, gastrointestinal adverse reactions, bone marrow suppression and fatigue. Therefore, the following management measures are recommended when using drugs in combination:

Regularly monitor blood pressure, blood routine, liver and kidney function and thyroid function.

Reasonably adjust the dose, and if necessary, reduce the dose of lenvatinib (e.g. 12 mg down to 8 mg).

Avoid combination chemotherapy in patients with high blood pressure and high bleeding risk, or strengthen monitoring.

Use supportive care (antihypertensive drugs, antiemetics, diuretics, etc.) to reduce side effects.

Through reasonable management, it is possible to maximize the efficacy while reducing the adverse reactions caused by the combination therapy and improving the patient's survival benefit and quality of life.

xa0

Reference materials:https://www.lenvima.com/